-

CRTO Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Criteo (CRTO)

Criteo guided investors to flat to low-single-digit growth in Contribution ex-TAC on May 6, 2026. On August 5, 2026, the Company revised that outlook to a decline of 10% to 12% at constant currency -- and the stock dropped.

NEW YORK--(BUSINESS WIRE)--Criteo S.A. (NASDAQ: CRTO) shareholders were told in May to expect flat to low-single-digit growth in full-year Contribution ex-TAC; on August 5, 2026, the Company cut that figure to a decline of 10% to 12% at constant currency, and shares fell sharply. If you lost money on Criteo stock, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The timeline is short. On the Q1 2026 earnings call held May 6, 2026, then-Chief Financial Officer Sarah Glickman stated: "For 2026, we now expect contribution ex-TAC to decline by low single digits at constant currency." On the same call, Chief Executive Officer Michael Komasinski stated: "We remain highly confident in the trajectory of our business, including our expectation of a return to growth in the fourth quarter and reacceleration into 2027."

Ninety-one days after the May 6, 2026 earnings call, Criteo reported Q2 2026 revenue of $428 million, down 11% year over year; net income of $12 million, down 49%; and adjusted EBITDA of $73 million, down 18%. The Company also reduced its full-year Contribution ex-TAC outlook to a 10%–12% decline at constant currency. Levi & Korsinsky is investigating potential securities law violations.

Criteo investors who suffered losses may request a free case evaluation here or call (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the CRTO Investigation

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Criteo made materially false or misleading statements regarding its fiscal 2026 Contribution ex-TAC outlook and business trajectory, and whether the Company adequately disclosed the factors affecting that outlook. When the Company disclosed on August 5, 2026 that it now expected a 10% to 12% decline at constant currency, the stock price declined sharply.

Q: When did Criteo allegedly mislead investors? A: The investigation concerns statements made before the August 5, 2026 corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: Who is eligible to participate in the CRTO investigation? A: Investors who purchased CRTO stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do CRTO investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my CRTO shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CRTO and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis -- no upfront fees, no retainer, and no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NASDAQ:CRTO

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

NEW YORK--(BUSINESS WIRE)--A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The...

ONT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Onterris, Inc. (ONT)

NEW YORK--(BUSINESS WIRE)--A guidance reduction of roughly $105 million at the midpoint sent Onterris, Inc. (NYSE: ONT) shares down approximately 17.5% to 18% on August 5, 2026. Shareholders who lost money on ONT are encouraged to have their losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The February 25, 2026 guidance assumed annual environmental emergency response revenue of $50.0 million to $70.0 million....

SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)

NEW YORK--(BUSINESS WIRE)--Roughly 90% of Sionna Therapeutics (SION) market value was erased after the Company released Phase 2a PreciSION CF results for SION-719, representing a decline of approximately $40 per share from the stock’s recent trading levels. If you held SION shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The impact on shareho...
Back to Newsroom